B-cell lymphoma idiotype antigen (Id)

The B-cell lymphoma idiotype antigen is the unique protein sequence found within the variable regions of the surface immunoglobulin expressed by a malignant B-cell clone. Since each B-cell undergoes unique V(D)J recombination, the resulting idiotype serves as a patient-specific, tumor-exclusive antigen that is absent from normal B-cells and other somatic tissues (Levy & Ronald, 2012, Expert Review of Vaccines). This high degree of specificity makes it an ideal target for active immunotherapy, particularly in indolent B-cell lymphomas like follicular lymphoma (Schuster et al., 2011, Journal of Clinical Oncology). Therapeutic strategies typically involve the production of personalized vaccines, where the idiotype protein is purified from the patient's tumor and conjugated to an immunogenic carrier, such as Keyhole Limpet Hemocyanin (KLH), to overcome the antigen's inherent low immunogenicity (Bendig et al., 2004, Current Topics in Microbiology and Immunology). Upon administration, these vaccines aim to elicit both humoral and cellular immune responses that specifically eliminate the malignant clone. However, the clinical utility of idiotype-based therapies has been limited by the logistical complexity of custom manufacturing and the potential for tumor escape through the selection of idiotype-negative variants (Inoges et al., 2006, Journal of the National Cancer Institute). Despite these challenges, the idiotype remains a cornerstone of research into personalized cancer vaccines and targeted immunotherapy.

Other names

Tumor-specific idiotypeClonal immunoglobulin idiotypeB-cell receptor idiotypeSurface immunoglobulin idiotypeIdiotypic determinant

Induction of a patient-specific active immune response, involving both B-cell (humoral) and T-cell (cellular) activation, against the unique variable regions of the clonal B-cell receptor to selectively eliminate malignant cells.